Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
Kidney Cancer · 2017
DOI: 10.3233/kca-170007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Cancer, 2017. Verfasst von Manuel Caitano Maia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
In a series of 224 patients with advanced renal cell carcinoma (RCC), we have previously reported circulating tumor DNA (ctDNA) detection in 79% of patients. Clinical factors associated with detection are unknown.
Methods
Data was obtained from patients with radiographically confirmed stage IV RCC who received ctDNA profiling as a part of routine clinical care using a CLIA-certified platform evaluating 73 genes. Detailed clinical annotation was performed, including assessment of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, previous and current treatments and calculation of tumor burden using scan data most proximal to ctDNA assessment. Tumor burden was equated to the sum of longest diameter (SLD) of all measurable lesions.
Results
Thirty-four patients were assessed (18 male and 16 female) with a median age of 62 (range, 34–84). Twenty-six patients, 4 patients and 4 patients had clear cell, sarcomatoid and papillary histologies, respectively. IMDC risk was good, intermediate and poor in 14, 19 and 1 patient, respectively. ctDNA was detected in 18 patients (53%) with a median of 2 genomic alterations (GAs) per patient. No associations were found between IMDC risk, histology or treatment type and presence/absence of ctDNA. However, patients with detectable ctDNA had a higher SLD compared to patients with no detectable ctDNA (8.81 vs 4.49 cm; P = 0.04). Furthermore, when evaluated as a continuous variable, number of GAs was correlated with SLD ( P = 0.01).
Conclusions
With the caveat of a limited sample size, it appears that SLD (a surrogate for tumor burden) is higher in mRCC patients with detectable ctDNA. Confirmation of these findings in larger series is ongoing and may suggest a capability for ctDNA to either complement or supplant radiographic assessment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
- Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
- Istanbul Medeniyet University Hospital, Istanbul, Turkey.
- City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
- Guardant Health, Inc., Redwood City, CA, USA.
Zitieren
APA
Maia, M. C., Bergerot, P. G., Dizman, N., Hsu, J., Jones, J., Lanman, R. B., Banks, K. C., & Pal, S. K. (2017). Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. Kidney Cancer. https://doi.org/10.3233/kca-170007
Vancouver
Maia MC, Bergerot PG, Dizman N, Hsu J, Jones J, Lanman RB, et al. Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. Kidney Cancer. 2017. doi:10.3233/kca-170007
BibTeX
@article{Maia2017,
author = {Maia, Manuel Caitano and Bergerot, Paulo Gustavo and Dizman, Nazli and Hsu, JoAnn and Jones, Jeremy and Lanman, Richard B and Banks, Kimberly C and Pal, Sumanta K},
title = {Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden},
journal = {Kidney Cancer},
year = {2017},
doi = {10.3233/kca-170007}
}
EUVIMED